GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pneumonia overview

Pneumonia is a serious infection that causes inflammation and fluid in the lungs. It can be caused by bacteria, viruses, fungi, or chemical irritants. It occurs in four stages: congestion, red hepatization, grey hepatization, resolution. Symptoms include cough, which may produce greenish, yellow, or even bloody mucus, fever, sweating and shaking chills. Complications from pneumonia include respiratory failure, sepsis, and lung abscess. Antibiotics are used for bacterial pneumonia. Antifungal medicines are prescribed to treat fungal pneumonia. Viral pneumonia is often mild and goes away on its own within a few weeks.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.